Karyopharm shareholders approve 450,000 share increase to equity plan at annual meeting

Karyopharm Therapeutics Inc.

Elected Garen G. Bohlin and Zhen Su as Class III directors with 3,066,819 and 3,191,845 votes for, respectively.
Approved amendment to 2022 equity plan adding 450,000 shares; 2,606,928 for, 1,103,365 against, 344,880 abstain.
Advisory vote on named executive officer compensation passed: 2,716,951 for, 1,041,611 against, 296,611 abstain.
Advisory vote on say-on-pay frequency favored every year (3,263,514 votes); Board adopted annual frequency.
Ratified Ernst & Young as independent auditor for FY2025: 6,237,926 for, 210,714 against, 115,566 abstain.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.